Intrathecal injection of dexmedetomidine ameliorates chronic neuropathic pain via the modulation of MPK3/ERK1/2 in a mouse model of chronic neuropathic pain

2019 ◽  
Vol 41 (12) ◽  
pp. 1059-1068 ◽  
Author(s):  
Yiling Qian ◽  
Qianlun Wang ◽  
Jiantong Jiao ◽  
Guilong Wang ◽  
Zhengfeng Gu ◽  
...  
2020 ◽  
Vol 11 (6) ◽  
pp. 1281-1286 ◽  
Author(s):  
Fatma Mufti ◽  
Young-Hwan Jung ◽  
Luigino Antonio Giancotti ◽  
Jinha Yu ◽  
Zhoumou Chen ◽  
...  

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Shuai Shao ◽  
Cheng-Bo Xu ◽  
Cheng-Juan Chen ◽  
Gao-Na Shi ◽  
Qing-Lan Guo ◽  
...  

Abstract Background Chronic neuropathic pain is a frequent sequel to peripheral nerve injury and maladaptive nervous system function. Divanillyl sulfone (DS), a novel structural derivative of 4,4′-dihydroxydibenzyl sulfoxide from a traditional Chinese medicine Gastrodia elata with anti-nociceptive effects, significantly alleviated neuropathic pain following intrathecal injection. Here, we aimed to investigate the underlying mechanisms of DS against neuropathic pain. Methods A chronic constrictive injury (CCI) mouse model of neuropathic pain induced by sciatic nerve ligation was performed to evaluate the effect of DS by measuring the limb withdrawal using Von Frey filament test. Immunofluorescence staining was used to assess the cell localizations and expressions of Iba-1, ASC, NLRP3, and ROS, the formation of autolysosome. The levels of NLRP3-related proteins (caspase-1, NLRP3, and IL-1β), mitophagy-related proteins (LC3, Beclin-1, and p62), and apoptosis-related proteins (Bcl-XL and Bax) were detected by Western blotting. The apoptosis of BV-2 cell and caspase activity were evaluated by flow cytometry. Results DS significantly alleviated the neuropathic pain by increasing the mechanical withdrawal threshold and inhibiting the activation of NLRP3 in CCI-induced model mice. Our findings indicated that DS promoted the mitophagy by increasing the LC3II and Beclin 1 and decreasing the levels of p62 protein in BV-2 cell. This is accompanied by the inhibition of NLRP3 activation, which was shown as inhibited the expression of NLRP3 in lysates as well as the secretion of mature caspase-1 p10 and IL-1β p17 in supernatants in cultured BV-2 microglia. In addition, DS could promote mitophagy-induced improvement of dysfunctional mitochondria by clearing intracellular ROS and restoring mitochondrial membrane potential. Conclusion Together, our findings demonstrated that DS ameliorate chronic neuropathic pain in mice by suppressing NLRP3 inflammasome activation induced by mitophagy in microglia. DS may be a promising therapeutic agent for chronic neuropathic pain.


2018 ◽  
Vol 14 ◽  
pp. 174480691880898 ◽  
Author(s):  
Anna Rita Zuena ◽  
Daniela Maftei ◽  
Giovanni Sebastiano Alemà ◽  
Francesca Dal Moro ◽  
Roberta Lattanzi ◽  
...  

Cells ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 547
Author(s):  
Dang Bao Son ◽  
Woosik Choi ◽  
Mingu Kim ◽  
Eun Jin Go ◽  
Dabeen Jeong ◽  
...  

Chemotherapy-induced neuropathic pain (CINP) is a severe adverse effect of platinum- and taxane-derived anticancer drugs. The pathophysiology of CINP includes damage to neuronal networks and dysregulation of signal transduction due to abnormal Ca2+ levels. Therefore, methods that aid the recovery of neuronal networks could represent a potential treatment for CINP. We developed a mouse model of paclitaxel-induced peripheral neuropathy, representing CINP, to examine whether intrathecal injection of decursin could be effective in treating CINP. We found that decursin reduced capsaicin-induced intracellular Ca2+ levels in F11 cells and stimulated neurite outgrowth in a concentration-dependent manner. Decursin directly reduced mechanical allodynia, and this improvement was even greater with a higher frequency of injections. Subsequently, we investigated whether decursin interacts with the transient receptor potential vanilloid 1 (TRPV1). The web server SwissTargetPrediction predicted that TRPV1 is one of the target proteins that may enable the effective treatment of CINP. Furthermore, we discovered that decursin acts as a TRPV1 antagonist. Therefore, we demonstrated that decursin may be an important compound for the treatment of paclitaxel-induced neuropathic pain that functions via TRPV1 inhibition and recovery of damaged neuronal networks.


2019 ◽  
Vol 45 (7) ◽  
pp. 1105-1114 ◽  
Author(s):  
Antony D. Abraham ◽  
Edward J. Y. Leung ◽  
Brenden A. Wong ◽  
Zeena M. G. Rivera ◽  
Lauren C. Kruse ◽  
...  

2021 ◽  
Vol 1758 ◽  
pp. 147329
Author(s):  
Kelli Somelar ◽  
Monika Jürgenson ◽  
Külli Jaako ◽  
Kaili Anier ◽  
Anu Aonurm-Helm ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document